



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

615.ACUTE MYELOID LEUKEMIAS: COMMERCIALLY AVAILABLE THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES

Clonal Dynamics and Deterministic Clinical Fate Mapping of Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukemia with TP53 Disruption

Shyam Ajay Patel, MDPhD¹, Benjamin Tanenbaum, MD², Asiri Ediriwickrema, MD³, Jan Cerny, MDPhD², Lloyd Hutchinson², Xiuling Meng², William K Gerber², Salwa Khedr, MD², William Selove⁴, Bruce Woda, MD², Jonathan M. Gerber, MD²

¹ Department of Medicine - Hematology/Oncology, UMass Chan Medical School, Worcester, MA

² UMass Chan Medical School, Worcester, MA

³ Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA

⁴ UMass Memorial Medical Center, Whitinsville, MA

Background: Myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) with multi-hit *TP53* comprise the highest risk subgroup of all myeloid malignancies. *TP53* aberration is recognized as a diagnostic category in the 2022 International Consensus Classification (ICC) and the 5th edition of the WHO. However, these systems do not discern among the subtypes of *TP53* aberrations regarding response to therapy. In this study, we explore the clonal dynamics that underlie such prognostic heterogeneity within distinct subgroups of *TP53*-aberrant MDS and AML, with a specific focus on the effect of hypomethylating agent (HMA) vs. araC-based chemotherapy on *TP53* variant allele frequency (VAF).

Methods: The UMass Leukemia Registry from the UMass Data Lake identified 76 patients harboring *TP53* aberration(s) plus ICD-10 code of either D46.9 (MDS and its subentities) or C92.00 (AML and its subentities) between 2011-2023. Data was integrated with hematopathology records. *TP53* exome sequencing was performed with coverage depth 500X to 6500X, and VAFs were adjusted for copy number variation (CNV), as previously described (Patel SA et al., *Leuk Lymphoma* 2021; 62: 3348-60). Patients with serial bone marrow biopsy samples were included. We defined multi-hit *TP53* status as per the ICC: two or more distinct *TP53* mutations with VAF \geq 10%, or a single *TP53* mutation plus one of the following abnormalities: (1) del(17p13.1), (2) *TP53* VAF $>$ 50%, (3) copy-neutral loss-of-heterozygosity, or (4) any complex karyotype. Clonal dynamics were assessed for MDS vs. AML and for varying *TP53* allelic states as a function of therapeutic intervention. Clinical fate mapping was performed based on management decisions at various points of clinical care.

Results: For patients with *TP53*-aberrant MDS, 17 patients underwent serial bone marrow biopsies during treatment. Of these, 11 (64.7%) had multi-hit status. Eight patients (47.1%) underwent hematopoietic cell transplant (HCT), and 7 of these 8 patients had received HMA-based front-line therapy. For patients with MDS, we assessed the effect of HMA-based therapy on *TP53* VAF. The mean *TP53* VAF (sum of VAFs) was significantly lower after HMA-based treatment (35% vs. 12.6%) ($p = 0.0075$) (**Panel A**). For patients with *TP53*-aberrant AML, 19 patients underwent serial bone marrow biopsies. Of these, 14 (73.7%) had multi-hit status. Only 2 patients (10.5%) underwent HCT. Five patients (26.3%) received araC-based induction, while 11 patients (57.9%) initially received HMA-based induction. For patients with AML with multi-hit *TP53*, we assessed the effect of HMA-based vs. araC-based front-line therapy on *TP53* VAF. HMA therapy led to mean fold reduction in *TP53* VAF (pre-treatment to post-treatment) of 11.7 ± 5.8 ($p = 0.019$), while araC-based therapy actually led to mean fold increase (but not statistically significant) in *TP53* VAF (pre-treatment to post-treatment) of 2.6 ± 1.05 ($p = 0.319$) (**Panel B**). HMA-based treatment resulted in significantly greater reduction in the VAF in aberrant clones and subclones compared to araC-based treatment. Compared to AML, most patients with MDS (62.9%) proceeded with palliative intent therapy at the time of diagnosis. Although patients with AML (53.7%) attempted to proceed with curative intent at the time of diagnosis, only 14.6% eventually proceeded with HCT, largely due to clinical decompensation or disease progression during front-line therapy. Among HCT recipients for MDS ($n = 10$), 7 (70%) remained in remission. Among HCT recipients for AML ($n = 6$), 4 (66.7%) remained in morphologic leukemia-free state.

Conclusion: There is limited literature on clonal and subclonal diversity in patients with MDS or AML with *TP53* aberrations. Such considerations constitute an important therapeutic issue, as certain interventions may only eliminate a fraction of a patient's mutant cells. In our study, HMA- and araC-based regimens had differential effects on various subclones: HMA was

more effective in reducing the *TP53* mutational burden and increasing patient ability to proceed with HCT. AraC-based therapy appeared less effective, perhaps due to selection pressure in favor of *TP53*-mutant cells. Prospective trials are required to identify optimal regimens that lead to the best long-term outcomes, and single-cell resolution might assist with more definitively assessing dynamics of clonal response to treatment.

Disclosures Patel: UMass Center for Clinical and Translational Science (CCTS) Pilot Project Program grant (NIH / NCATS Grant UL1TR001453: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. **Cerny:** MERIT CRO: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Actinium Pharmaceuticals: Current holder of stock options in a privately-held company; BlueBird Bio, Inc: Current holder of stock options in a privately-held company; Cellectar Sciences: Current holder of stock options in a privately-held company; Dynavax Technologies: Current holder of stock options in a privately-held company; Gamida Cell: Current holder of stock options in a privately-held company; Atyr Pharma: Current holder of stock options in a privately-held company; Novavax Inc: Current holder of stock options in a privately-held company; Ovid Therapeutics Inc: Current holder of stock options in a privately-held company; Sorreto Therapeutics: Current holder of stock options in a privately-held company; Veru Inc: Current holder of stock options in a privately-held company; Viridian Therapeutics: Current holder of stock options in a privately-held company; Vaxart Inc: Current holder of stock options in a privately-held company; 2Seventy Bio Reg SHS: Current holder of stock options in a privately-held company; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ICON- Prolacta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ICON- Allovir: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. **Gerber:** AbbVie: Divested equity in a private or publicly-traded company in the past 24 months; Novartis: Honoraria, Research Funding; Hutchmed: Research Funding; Bristol Myers Squibb: Research Funding; Stemline Therapeutics, Inc.: Research Funding.




Figure 1

<https://doi.org/10.1182/blood-2023-181945>